Metabolomic Exploration of Dysregulated Lipid Metabolism in MFN2-related CMT2A (MetaDLM_CMT2A)

Last updated: December 9, 2024
Sponsor: University Hospital, Angers
Overall Status: Completed

Phase

N/A

Condition

Neuropathy

Peripheral Neuropathy

Treatment

blood sample

Clinical Study ID

NCT04881201
2021-A00834-34
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Charcot-Marie-Tooth (CMT) disease is the commonest sensitivo-motor inherited peripheral neuropathies with a prevalence of about 10-30 per 100,000. To date, more than 80 genes have been found responsible for CMT. Some of these genes code for mitochondrial proteins such as mitofusin 2 (MFN2).

In the last few years, our laboratory has developed strong expertise in metabolomics. The MetaDLM_CMT2A project proposes to produce metabolomic and lipidomic maps in CMT2A plasma from a cohort of genetically and clinically characterized patients with a national recruitment.

In the perspective of future clinical trials, these biomarkers and the better understanding of lipid metabolism defects in CMT2A would be of major interest in monitoring the evolution of the disease and developing specific therapeutic approaches.

Eligibility Criteria

Inclusion

Inclusion Criteria:

For all participants :

  • Adult person

  • Person on an empty stomach at the time of inclusion

  • Person who signed the study participation consent form

  • Person affiliated or beneficiary of a social security scheme

Patients Charcot-Marie-Tooth :

  • Patient with symptoms of Charcot-Marie-Tooth disease on clinical examinationclinical examination

  • Patient with axonal neuropathy confirmed by an electrophysiological studyelectrophysiological study with a median nerve conduction velocity > 38 m / s

  • Patient with documented pathogenic mutation (class 4 or class 5) in the MFN2 orpatient with a variant of uncertain significance, as determined by the laboratoryperforming the test, if the variant of unknown significance has been found in foundin multiple affected individuals in a family and not found in unaffected familymembers in unaffected family members.

Control subject :

  • Each control is matched in age and sex to a case previously included in the study.

Exclusion

Exclusion Criteria:

For all participants :

  • Pregnant, breastfeeding or parturient woman

  • Person deprived of liberty by judicial or administrative decision

  • Person subject to forced psychiatric care

  • Person subject to a legal protection measure

  • Person unable to give consent

Patients Charcot-Marie-Tooth :

  • Patient with a neuropathy other than CMT2A (such as diabetic neuropathy or any othercause of acquired neuropathy) neuropathy or any other cause of acquired neuropathy),medical history of kidney stones kidney stones or cardiovascular risk factors (dyslipidaemia diabetes, severe obesity (BMI >35 kg/m²))

  • Patient treated with Idebenone at the time of inclusion. (It is possible to includea patient treated with Idebenone if the treatment was interrupted at least 5 daysbefore)

Control subject :

  • Person with neuropathy, medical history of kidney stones or cardiovascular riskfactors cardiovascular risk factors (dyslipidaemia, diabetes, severe obesity (BMI >35 kg/m²))

Study Design

Total Participants: 47
Treatment Group(s): 1
Primary Treatment: blood sample
Phase:
Study Start date:
January 05, 2022
Estimated Completion Date:
June 10, 2024

Connect with a study center

  • CHU

    Angers, Maine Et Loire 49933
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.